A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer

Trial Profile

A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Seliciclib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms APPRAISE
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 21 Dec 2010 Primary endpoint 'Progression-free-survival' has not been met, according to a Cyclacel Pharmaceuticals media release.
    • 21 Dec 2010 Top-line results reported in a Cyclacel Pharmaceuticals media release.
    • 05 Aug 2010 Top-line results are expected in 2010, according to a Cyclacel Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top